Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
Agenus Inc. seeks stockholder approval of equity proposals while summarizing 2025–early 2026 clinical, commercial and financial progress. Management highlights durable BOT+BAL survival data presented at ESMO, reimbursed compassionate-access revenues recognized in France, enrollment start of the registrational Phase 3 BATTMAN trial, and a transaction that improved liquidity.
The proxy asks for (i) a 5,000,000-share increase to the 2019 Equity Incentive Plan and (ii) a one-time option exchange with executive/director replacement options struck at 150% of the exchange-date market price. The CEO urges support to preserve the team and continue BATTMAN, expanded access, and regulatory engagement.
HARRISON THOMAS L reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director Thomas L. Harrison received 9,228 shares of common stock as a grant under the company’s Board Compensation Election Policy. These shares represent director fees taken in stock rather than cash at an average price of $3.319 per share. After this award, Harrison directly holds 38,998 common shares.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,629 shares of Common Stock as fully vested compensation in lieu of cash salary for the pay period ending April 3, 2026. The shares were valued using the $3.33 closing price on April 2, 2026. After this grant, he directly holds 339,147 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares through a GRAT and a partnership in which he has investment authority and a partial pecuniary interest.
Agenus Inc. director Timothy Wright received a grant of Deferred Stock Units as part of his board compensation. On April 1, 2026, he acquired 2,448.256 Deferred Stock Units, each tied to one share of Agenus common stock under the company’s Directors' Deferred Compensation Plan.
Following this award, Wright holds a total of 26,361.262 Deferred Stock Units. These units generally convert into the same number of common shares, typically when he ceases to serve as a director. The April 1, 2026 units were valued at $3.319 each, based on the average closing price of Agenus common stock during the prior calendar quarter.
Agenus Inc — The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A stating it currently reports 0 shares of beneficial ownership in Agenus following an internal realignment. The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains certain Vanguard subsidiaries now report separately. The filing is signed by Ashley Grim on 03/26/2026.
Agenus Inc. reports a favorable court ruling in a securities case. On March 24, 2026, the U.S. District Court for the District of Massachusetts dismissed in full a putative securities class action, Byron Olsen v. Agenus Inc. et al., alleging violations of federal securities laws related to the company’s public disclosures.
The court granted the defendants’ motion to dismiss the amended complaint in its entirety and also denied the plaintiff’s request for leave to amend, effectively ending this lawsuit in favor of Agenus and the named individual executives.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 3,983 shares of Common Stock as fully vested compensation, in lieu of cash salary, for the pay period ending March 20, 2026. The shares were valued at $3.71, the closing price on March 20, 2026, and issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. Following the grant, he holds 334,518 shares directly, plus additional indirect holdings through IRA accounts and entities including the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.
Agenus Inc. files its annual report describing a clinical-stage immuno-oncology business centered on its botensilimab/balstilimab cancer program and related partnerships.
The company reported a net loss of $3.1 million for 2025, a sharp improvement from $232.3 million and $257.4 million in 2024 and 2023, but still has no approved products. Cash and cash equivalents were $3.0 million as of December 31, 2025, and management expects existing resources plus early 2026 funding to support critical needs into 2027 while acknowledging going concern risks and a need for more capital. The report highlights encouraging survival and response data for botensilimab plus balstilimab in refractory microsatellite-stable colorectal cancer and other tumors, early reimbursed access in France, and a $91.0 million collaboration with Zydus that includes sale of manufacturing facilities. It also notes deconsolidation of MiNK, ongoing SaponiQx adjuvant work, intense competition, and extensive risk factors tied to financing, regulatory approvals, manufacturing, and reliance on a single lead program.
Agenus Inc. reported fourth-quarter 2025 operating income of $14.4 million and a full-year 2025 operating loss of $20.2 million, driven by growing collaboration and pre-commercial revenues. Pre-commercial product revenue from early access use of BOT+BAL reached $3.2 million in Q4 and $4.2 million for the year, while other revenue, including non-cash royalty revenue, totaled $31.1 million for Q4 and $110.0 million for 2025.
The BOT+BAL immunotherapy program advanced significantly. Agenus initiated the global Phase 3 BATTMAN registrational trial in refractory microsatellite-stable metastatic colorectal cancer, targeting about 830 patients at more than 100 sites. Clinical data in heavily pretreated MSS mCRC showed a two-year overall survival of 42% and approximately 21-month median overall survival, compared with previously reported 10–14 months for standard therapies.
Commercial readiness also progressed through early access programs and a major manufacturing partnership. France’s AAC program expanded reimbursed access to ovarian cancer and sarcoma, and paid named-patient programs generated over 200 inquiries from more than 30 countries. A strategic collaboration with Zydus Lifesciences delivered $91 million in upfront capital, subject to closing adjustments, plus a $20 million contingent payment, while securing dedicated U.S. biologics manufacturing capacity for BOT+BAL.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,994 shares of common stock on March 6, 2026 as a stock-paid salary award. The shares were valued at $2.96 per share, the closing price of Agenus common stock on March 6, 2026, and represent his net salary for the pay period ending that date.
After this grant, Dr. Armen directly held 330,535 Agenus common shares. Additional shares are held indirectly in his IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has investment authority or a partial pecuniary interest.